Comprehensive medication guide to Lagevrio including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$10–$50 copay for most insured patients; Tier 1 on most Medicare Part D plans; most private insurance plans cover it with standard copays. Prior authorization generally not required.
Estimated Cash Pricing
$1,100–$1,170 retail for a full 5-day course (40 capsules); as low as ~$993 with GoodRx coupons at participating pharmacies. No generic version is available.
Medfinder Findability Score
45/100
Summarize with AI
On this page
Lagevrio is the brand name for molnupiravir, an oral antiviral medication made by Merck Sharp & Dohme LLC (in collaboration with Ridgeback Biotherapeutics). It is authorized under FDA Emergency Use Authorization (EUA) for the treatment of mild-to-moderate COVID-19 in high-risk adults. Lagevrio is taken as four 200 mg capsules (800 mg total) orally twice daily for 5 days — a total of 40 capsules.
Lagevrio is prescribed for adults who test positive for COVID-19, are at high risk for progression to severe disease (hospitalization or death), are within 5 days of symptom onset, and for whom other authorized COVID-19 treatments such as Paxlovid or Remdesivir are not accessible or clinically appropriate.
Lagevrio has not received full FDA approval — it operates under an Emergency Use Authorization. It is not authorized for patients under 18, for use in pregnancy, or for hospitalized COVID-19 patients.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Lagevrio (molnupiravir) is a nucleoside analogue prodrug. After oral ingestion, it is rapidly converted to its active form — N4-hydroxycytidine (NHC) — by esterases in the blood. NHC is then taken up by virus-infected cells and phosphorylated to its triphosphate form (NHC-TP).
NHC-TP closely resembles a natural RNA building block and gets incorporated into the SARS-CoV-2 genome by the viral RNA polymerase (nsp12/RdRp). Because NHC can pair with the wrong base during replication, each incorporation causes a mutation. As the virus continues copying itself — incorporating NHC multiple times — errors accumulate until the viral genome becomes non-functional. This mechanism is known as viral error catastrophe or lethal mutagenesis.
Unlike Paxlovid (which blocks a viral protease enzyme), Lagevrio works at the genetic level — which is why it has minimal drug interactions. However, this mechanism also raises concerns about potential incorporation into human DNA, which is why it is contraindicated in pregnancy and not authorized for pediatric patients.
200 mg — capsule
Standard dosing: 4 capsules (800 mg total) orally every 12 hours for 5 days. Take with or without food. Swallow whole — do not open, break, or crush capsules.
Lagevrio is one of the more difficult COVID-19 medications to locate at retail pharmacies in 2026. While it is not on the FDA's official drug shortage list, real-world availability is inconsistent. Many retail pharmacies — especially chain pharmacies — do not routinely stock Lagevrio due to its lower prescription volume (it is a second-line treatment) and the high cost ($1,100+ per course) which creates financial risk for pharmacies if the medication expires unused.
The transition from government-distributed supply to commercial-only channels (completed in early 2024) and the expiration of all HHS-distributed stock by February 2025 have compounded the access problem. Hospital outpatient pharmacies and independent community pharmacies are more likely to carry it.
Because Lagevrio must be started within 5 days of symptom onset, finding it quickly is critical. medfinder contacts pharmacies near you to check which ones have Lagevrio in stock and texts you the results — saving time when every hour counts.
Under the FDA Emergency Use Authorization terms, Lagevrio may be prescribed by any healthcare provider licensed to prescribe medications in the anti-infective drug class under their state's laws. Lagevrio is not a controlled substance, so no DEA registration is required. However, prescribers must provide patients with the EUA Fact Sheet and document receipt.
Physicians (MDs and DOs) — including primary care, infectious disease, urgent care, and hospitalists
Advanced Practice Registered Nurses (APRNs) and Nurse Practitioners (NPs) — in states where they have independent prescriptive authority for anti-infectives
Physician Assistants (PAs) — where authorized to prescribe anti-infectives under state law
Note: Unlike Paxlovid, pharmacists generally cannot prescribe Lagevrio. Telehealth providers can evaluate patients and prescribe Lagevrio for eligible high-risk adults, making telehealth a fast option for patients who cannot easily access in-person care.
No. Lagevrio (molnupiravir) is not a controlled substance. It is not scheduled under the DEA's Controlled Substances Act. You do not need a DEA-registered prescriber to prescribe it, and there are no federal restrictions on prescription quantities, refills, or how the prescription can be transmitted (e.g., electronic, phone, or fax).
However, Lagevrio does operate under FDA Emergency Use Authorization (EUA), which has its own prescribing requirements. Prescribers must be licensed to prescribe anti-infectives under state law, and they must provide patients with the EUA Fact Sheet before dispensing the medication. These are regulatory, not controlled substance, requirements.
Most patients tolerate Lagevrio well over the 5-day course. The most commonly reported side effects include:
Diarrhea (most common)
Nausea
Dizziness (may be worsened by alcohol)
Severe allergic reactions (anaphylaxis): feeling faint, trouble breathing, facial swelling, hives — stop medication and seek emergency care immediately
Potential fetal harm (boxed warning): NOT recommended in pregnancy — animal studies showed teratogenicity and embryofetal lethality
Theoretical risk of mutagenicity: basis for contraindication in pregnancy and exclusion of patients under 18
Know what you need? Skip the search.
Paxlovid (nirmatrelvir/ritonavir)
First-line oral antiviral for COVID-19. FDA-approved (May 2023). ~89% reduction in hospitalization/death in original trials. Significant drug interactions due to ritonavir component. More widely stocked than Lagevrio.
Remdesivir (Veklury)
FDA-approved IV antiviral for COVID-19. Given as 3-day outpatient infusion. Strong clinical evidence. Requires infusion center access — less convenient than oral options but a solid alternative when pills aren't viable.
Supportive care (rest, hydration, fever management)
For patients who cannot access any antiviral, supportive care including rest, fluids, and acetaminophen/ibuprofen for symptoms remains important, with close monitoring for signs of clinical deterioration.
Prefer Lagevrio? We can find it.
Alcohol
minorNo direct pharmacokinetic interaction. However, heavy alcohol use can impair immune function and may worsen dizziness (a known side effect). Avoid alcohol during the 5-day course.
Pregnancy / Drugs affecting fetal development
majorNot a drug interaction per se, but Lagevrio carries a boxed warning for potential fetal harm based on animal teratogenicity data. Contraindicated in pregnancy unless benefits outweigh risks.
Other medications (general)
minorNo formal drug-drug interactions have been identified for Lagevrio based on current EUA data. No CYP450 interactions identified. Always disclose full medication list to prescriber before starting.
Lagevrio (molnupiravir) fills a critical niche in COVID-19 treatment: an oral antiviral for patients who cannot safely take Paxlovid due to drug interactions or other contraindications. Its lack of known drug interactions makes it uniquely valuable for patients on complex medication regimens — particularly organ transplant recipients, cardiac patients, and those with neurological conditions requiring enzyme-inducing medications.
The key challenges with Lagevrio in 2026 are availability and cost. With government distribution programs ended and all HHS-distributed stock expired, patients must obtain Lagevrio through commercial pharmacies — which don't always keep it in stock. The 5-day treatment window makes speed essential. The MerckHelps program provides an important safety net for uninsured patients.
If you have been prescribed Lagevrio and need to find it at a pharmacy near you, medfinder can contact pharmacies on your behalf to locate available stock and text you the results — helping you get treated within the critical treatment window.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini